Antihypertensive Treatments In Patients Affected By Aortic Valve Stenosis

Research output: Contribution to journalArticle

Abstract

Systemic hypertension and aortic valve stenosis (AVS) are both age-related diseases. Severe aortic stenosis affects ≈2% to 5% of adults age > 65 years. Systemic hypertension (HTN) is a frequent comorbidity in patients with AVS and is coexistent for a longer period of time before AVS is treated. Essential systemic hypertension, per se, plays an important role in the creation of lesions on the aortic side of the valve, the region of higher exposure to tension stress. The subsequent endothelial defect represents the principal site of inflammatory process and oxidative stress, leading to aortic sclerosis and calcification. In this review, we want to describe the pharmacological features of the common antihypertensive drugs, analysing the recent literature, in order to achieve useful and updated information about the best treatment of systemic hypertension in patients with concomitant severe aortic stenosis.

Original languageEnglish
JournalCurrent Pharmaceutical Design
Publication statusE-pub ahead of print - Nov 23 2016

Fingerprint

Aortic Valve Stenosis
Antihypertensive Agents
Hypertension
Therapeutics
Sclerosis
Aortic Valve
Comorbidity
Oxidative Stress
Pharmacology

Keywords

  • Journal Article

Cite this

@article{622cffb03c1140a788c9addbfde91af2,
title = "Antihypertensive Treatments In Patients Affected By Aortic Valve Stenosis",
abstract = "Systemic hypertension and aortic valve stenosis (AVS) are both age-related diseases. Severe aortic stenosis affects ≈2{\%} to 5{\%} of adults age > 65 years. Systemic hypertension (HTN) is a frequent comorbidity in patients with AVS and is coexistent for a longer period of time before AVS is treated. Essential systemic hypertension, per se, plays an important role in the creation of lesions on the aortic side of the valve, the region of higher exposure to tension stress. The subsequent endothelial defect represents the principal site of inflammatory process and oxidative stress, leading to aortic sclerosis and calcification. In this review, we want to describe the pharmacological features of the common antihypertensive drugs, analysing the recent literature, in order to achieve useful and updated information about the best treatment of systemic hypertension in patients with concomitant severe aortic stenosis.",
keywords = "Journal Article",
author = "Paolo Poggio and Gianluca Folesani and Raffa, {Giuseppe M} and Paola Songia and Vincenzo Valenti and Veronika Myasoedova and Alessandro Parolari",
year = "2016",
month = "11",
day = "23",
language = "English",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Antihypertensive Treatments In Patients Affected By Aortic Valve Stenosis

AU - Poggio, Paolo

AU - Folesani, Gianluca

AU - Raffa, Giuseppe M

AU - Songia, Paola

AU - Valenti, Vincenzo

AU - Myasoedova, Veronika

AU - Parolari, Alessandro

PY - 2016/11/23

Y1 - 2016/11/23

N2 - Systemic hypertension and aortic valve stenosis (AVS) are both age-related diseases. Severe aortic stenosis affects ≈2% to 5% of adults age > 65 years. Systemic hypertension (HTN) is a frequent comorbidity in patients with AVS and is coexistent for a longer period of time before AVS is treated. Essential systemic hypertension, per se, plays an important role in the creation of lesions on the aortic side of the valve, the region of higher exposure to tension stress. The subsequent endothelial defect represents the principal site of inflammatory process and oxidative stress, leading to aortic sclerosis and calcification. In this review, we want to describe the pharmacological features of the common antihypertensive drugs, analysing the recent literature, in order to achieve useful and updated information about the best treatment of systemic hypertension in patients with concomitant severe aortic stenosis.

AB - Systemic hypertension and aortic valve stenosis (AVS) are both age-related diseases. Severe aortic stenosis affects ≈2% to 5% of adults age > 65 years. Systemic hypertension (HTN) is a frequent comorbidity in patients with AVS and is coexistent for a longer period of time before AVS is treated. Essential systemic hypertension, per se, plays an important role in the creation of lesions on the aortic side of the valve, the region of higher exposure to tension stress. The subsequent endothelial defect represents the principal site of inflammatory process and oxidative stress, leading to aortic sclerosis and calcification. In this review, we want to describe the pharmacological features of the common antihypertensive drugs, analysing the recent literature, in order to achieve useful and updated information about the best treatment of systemic hypertension in patients with concomitant severe aortic stenosis.

KW - Journal Article

M3 - Article

C2 - 27881062

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

ER -